Abstract: Development of an alternative process to conventional toxic chromic acid anodization (CAA) with equivalent corrosion resistance is a challenging task. The present invention provides a chromate free process for the manufacture of corrosion resistant sealed anodized coating for long term corrosion resistance of aerospace grade aluminum alloy. This method includes the steps of cleaning, chemical etching, anodizing in Tartaric-Sulphuric acid electrolyte followed by dipping the specimen in the sealing bath containing at least two water soluble either Mn and Mo or Mn and V oxyanions as corrosion inhibitors and a sufficient amount of alkali metal ion based nitrates at a temperature range between 60 and 80° C. for about 20 to 40 minutes at a pH range of 7 to 9. The sealed anodic coatings developed from this invention showed improved corrosion resistance in neutral 5% NaCl fog environment for greater than 2000 h of exposure.

Abstract: The present invention pertains to a method for consolidated bio processing of lignocellulosic biomass to L-Lactic acid. Particularly, the present invention relates to the production of L-Lactic Acid from low cost non edible feedstock lignocellulosic biomass. More particularly the present invention relates to the process for one step production of L-Lactic Acid from lignocellulosic biomass using thermophilic bacteria Paenibacillus macerans IIPSP3 (MTCC 5569), which is not only capable of hydrolyzing cellulose to glucose but also further fermenting it to L-Lactic Acid under aerobic conditions, without any growth inhibition in presence of lignin. The present invention provides a process which has less chances of contamination, as the fermentation is carried out at higher temperatures and is economically attractive, as preferably no external enzyme loadings are required.

Abstract: The invention disclosed herein provides tunable process for the preparation of water dispersive, biocompatible, fluorescent L-cysteine labeled gold (Au) quantum clusters without using any toxic reactants. Further the invention discloses application of synthesized fluorescent gold (Au) quantum clusters in the field of nano-medicine, fluorescence imaging and florescence based sensors.

Abstract: The present invention relates to a facile process for the preparation of non-covalently cross-linked self-assembled perylene bisimide nano structures using hydrogen bonding interactions with poly-4-vinyl pyridine or oligophenylene vinylene (OPV) as structural motif.

Abstract: The present invention relates to newer generation of triazoles, tetrazoles, isoxazoles, urea and sulphonamide functionalities containing 6-nitro-2,3-dihydronitroimidazooxazoles agents of formula 1, their method of preparation, and their use as drugs for treating Mycobacterium tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents. In the present invention, new generation 6-nitro-2,3-dihydronitroimidazooxazoles agents also show acceptable pharmacokinetic properties and synergistic or additive effects with known anti-tubercular drugs.

Abstract: The invention disclosed herein relates to novel Peribysin E analogs of general formula-I. Further the invention provides simple, economical and short synthesis of Peribysin E and its analogs of Formula I, in good yield and purity leading to the identification of more potent cell adhesion inhibitors.

Abstract: The present invention relates to the mannose-receptor selective lysinylated cationic amphiphile and a process for preparation thereof. The compounds of the present invention can target DNA vaccines to antigen presenting cells (APCs) such as macrophages and dendritic cells (DCs), via mannose receptors expressed on the cell surface of APCs. The cationic amphiphiles disclosed herein show enhanced cellular and humoral immune response compared to their mannosyl counterparts in genetic immunization in mice. The present invention discloses that immunization with electrostatic complexes (lipoplexes) of DNA vaccines encoding melanoma antigens (gp100 and tyrosinase) and liposome of the presently described novel lysinylated cationic amphiphiles with mannose-mimicking shikimoyl head-groups provides long-lasting (100 days post melanoma tumor challenge) protective immunity in all immunized mice.

Abstract: The present invention provides a process for the preparation of phosphor aerogel of uniform size having high porosity, low density; high thermal insulation and high luminescence, which is useful for various applications like lighting, display, sensing and other applications. More specifically, the present invention provides a simple and versatile process for the formation of monolithic gel, at room temperature, which on further drying at supercritical temperature and pressure result in dry aerogel. Further, annealing under mild reduced atmosphere from 1000°-1400° C. not only retains the porous network with uniform size particles but also crystallizes to form a phosphor aerogel having brightest luminescence with bulk density as low as 100 kg m-3, and strong enough to support a weight much higher than its own weight.

Abstract: A screw type dental implant system (1), having a dental implant fixture (2), a multifunctional component (3) and an abutment screw (4). The screw shape dental implant fixture has an external surface having buttress threads on the body and micro threads at the collar. This combination provides the advantages of: improved biomechanics at the implant abutment interface, self-tapping nature to the implant, and minimizing the stresses at the crest of the bone leading to decrease resorption of crestal bone. The multifunctional component serves the purposes of implant mount, impression analog and final abutment and has a single prosthetic platform so one component is compatible with different implant dimensions, which minimizes the inventory needed for the implant system and allows easy handling of the system. The multifunctional component also has an external concave transmucosal portion for enhancing the emergence profile and internal threads for securing the abutment screw.

Abstract: The present invention discloses a process for synthesis of piperidine alkaloids selected from fagomine, 4-epi-fagomine and nojirimycin from tri-O-benzyl-D-glucal or tri-O-benzyl-D-galactal.

Abstract: A regioselective N-Heterocyclic Carbene (NHC) catalyzed one step process for high yield synthesis of ?-acyloxy carbonyl compounds is disclosed.

Abstract: The invention disclosed herein relates to novel ligands (Lx) of Formula-I for selective detection of Cr (III) in pure aqueous medium and industrially viable process for the preparation thereof. Further the invention provides the process of selective detection of Cr (III) by fluorimetry using novel ligands of Formula-I. The invention also discloses a method of solubilizing novel ligands of formula-I in pure aqueous medium with the aid of non-ionic surfactant. The invention discloses a method of selective detection of Cr (III) using novel ligands of Formula-I.

Abstract: The present invention provides the compound Ormeloxifene [3, 4-trans-2,2-dimethyl-3-phenyl-4-p-(beta-pyrrolidinoethoxy) phenyl-7-methoxy chroman] as useful in inducing differentiation in wide range of myeloid leukemias including acute promyelocytic leukemia, acute myeloid leukemia and chronic myeloid leukemia where block in differentiation is common feature. Ormeloxifene induced differentiation that is marked by increase in differentiation marker proteins like C/EBP? and surface proteins such as cd11b and granulocyte colony stimulating factor receptor (GCSFr). Differentiated cells having neutrophil like morphology were observed when treated with 1.0 uM to 7.5 uM ORM which clearly indicates that ORM can induce differentiation in myeloid leukemia cells. At higher doses (5 uM to 7.5 uM) there is early onset of myeloid differentiation (24 to 48 h) with reduced no. of cells which is likely due to apoptotic effects of ORM at higher does.

Abstract: The present invention relates to novel tricyclic compounds of formula (I) and (II) More particularly, the present invention relates to novel tricyclic compounds of formula (I) and (II) and process of preparation of these compounds from 4,5-di-methyl-o-phenylinediamine. Further, the present invention relates to a process for preparation of tricyclic compound hunanamycin A.

Abstract: The present invention relates to new generation of triazole functionality containing 6-nitro-2,3-dihydroimidazooxazole agents for general formula I, their method of preparation and their use as drugs for treatment of tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents.

Abstract: Potentially degradable isohexide based compounds and their polymers, derived from renewable resources, are described. Degradable isohexide-based monomers and polymers obtained from renewable resources are also described. Finally, processes for synthesizing such degradable polymers via copolymerization of the isohexide-based monomers and long chain diols are disclosed.

Abstract: The present invention relates to the polyprenylated phloroglucinol compounds of formulae I and II. The present invention also provides synthesis and p-glycoprotein induction activity of the alkyl- and acyl-polyprenylated phloroglucinol compounds. Further, use of the compounds as p-glycoprotein inducers and methods of treatment of Alzheimer's disease using compounds of the invention are also provided.

Abstract: The present invention discloses organocatalytic process for asymmetric synthesis of highly enantioselective decanolide compounds in high yield with >99% ee. Further, the present invention disclose cost effective, improved organocatalytic process for asymmetric synthesis of highly enantioselective decanolides compounds from non-chiral, cheap, easily available raw materials.

Abstract: The present invention relates to a process for the separation of enantiomers or resolution of racemic mixtures using high surface area core-shell polymer beads. The present invention further relates to a core-shell functionalized polymer comprising a core which comprises copolymer made from monomers selected from non-aromatic acrylate, ethylene dimethacrylate and divinyl-benzene, a shell which comprises monomers selected from glycidyl ethers of methacrylate and a chiral selector selected from tartaric acid derivatives and amino acids.

Abstract: The present invention relates to new generation of triazole functionality containing 6-nitro-2,3-dihydroimidazooxazole agents for general formula I, their method of preparation and their use as drugs for treatment of tuberculosis, MDR-TB and XDR-TB either alone or in combination with other anti-tubercular agents.